An interventional study of Radiofrequency ablation of lumbar medial branch nerves. in Lumbar Spondylosis, sponsored by Milton S. Hershey Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Spondylosis with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Spondylosis · United States.
Among the 63 studies in Spondylosis with a site in United States, this one is the 34th largest by planned enrollment of the 45 interventional ones that give a count, is the only one that started in 2027, is one of 34 with no phase, reaches primary completion later than 17 of the 17 other live ones, and was the 54th registered.
142 studies on the registry are indexed under Spondylosis; 41 are open to participants now.
Browse Spondylosis studies →17 of the 63 studies in Spondylosis with a site in United States are open now. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 18+
EicOsis Human Health Inc. · Sites in United States
Ages 18+
University of Arkansas · Sites in United States
Ages 18+
University of New Mexico · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Spondylosis studies recruiting now, 12 (44%) set no upper age limit and 10 (37%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 60 across 101 interventional studies indexed under Spondylosis.
Median enrollment 45 across the 45 interventional studies, 78 across the 18 observational. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 63 have an industry lead sponsor. The 10 most frequent:
Milton S. Hershey Medical Center is the lead sponsor of 493 studies on the registry; 60 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.
Milton S. Hershey Medical Center has 1 study filed under Spondylosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Spondylosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04140344Duke UniversityThe NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions | 2026-12 |
| NCT06268704University of New MexicoParticulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection | 2027-01-01 |
| NCT05356286University of California, Los AngelesRecording of Intraoperative Spinal Cord Stimulation and Monitoring | 2027-01-22 |
| NCT05029726John O'TooleRegional Anesthesia in Minimally Invasive Lumbar Spine Surgery | 2027-02-01 |
| NCT06361485R3 Stem CellSafety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 63 studies in Spondylosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this voluntary research study is to determine whether the parasagittal approach to lumbar medial branch (LMB) nerve radio frequency ablation (RFA) will have greater efficacy than the traditional approach to lumbar medial branch nerve radio frequency ablation.
To determine whether the parasagittal approach to lumbar medial branch (LMB) nerve radiofrequency ablation (RFA) will have greater efficacy than the traditional approach to lumbar medial branch nerve radiofrequency ablation.
This will be accomplished by comparing the results between the newly proposed parasagittal approach and the traditional approach of medial branch RFA done on the same patient (different sites) with bilateral low back pain (LBP).
Traditional approach:
The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament (MAL) that may be ossified in up to 10% of the normal spine and, in such cases, potentially prevent proper coagulation of the medial branch nerve during the RFA procedure.
Parasagittal (new) approach:
Recently, Tran et al. showed that MAL is located more dorsally than it was thought earlier and, therefore, can't interfere with nerve coagulation during the RFA. Consequently, they proposed abandoning the 20-degree angle used for the traditional approach and placing the radiofrequency cannula parasagittally and more dorsally. It is proposed that, in order to achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo bilateral RFA; the right side will be done following the traditional approach, and the left side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.
Procedure: Radiofrequency ablation of lumbar medial branch nerves.
Patients will undergo bilateral RFA; the left side will be done following the traditional approach, and the right side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.
Procedure: Radiofrequency ablation of lumbar medial branch nerves.
Traditional approach: The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve. Parasagittal (new) approach: The RF cannula is placed parasagittally and more dorsally. The remainder of the procedure does not differ from the traditional method.
The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores).
The patients will describe the pain intensity using NRS - 11-point numeric rating scale, with 0 means no pain, and 10 - the worst possible pain intensity.
Time frame: Baseline
The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores).
The patients will describe the pain intensity using NRS - 11-point numeric rating scale, with 0 means no pain, and 10 - the worst possible pain intensity.
Time frame: 1 month post-procedure.
The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores).
The patients will describe the pain intensity using NRS - 11-point numeric rating scale, with 0 means no pain, and 10 - the worst possible pain intensity.
Time frame: 6 months post-procedure.
Oswestry Disability index (ODI)
10 questions assessing the functional impairment by the pain, using a 50 point scale, with 0 meaning no disability, and 50 meaning complete disability.
Time frame: Baseline
Oswestry Disability index (ODI)
10 questions assessing the functional impairment by the pain, using a 50 point scale, with 0 meaning no disability, and 50 meaning complete disability.
Time frame: 1 month post-procedure.
Oswestry Disability index (ODI)
10 questions assessing the functional impairment by the pain, using a 50 point scale, with 0 meaning no disability, and 50 meaning complete disability.
Time frame: 6 months post-procedure.
Number of subjects who ceased requiring analgesia
The patients will self-report their analgesic consumption.
Time frame: Baseline
Number of subjects who ceased requiring analgesia
The patients will self-report their analgesic consumption.
Time frame: 1 month post-procedure
Number of subjects who ceased requiring analgesia
The patients will self-report their analgesic consumption.
Time frame: 6 months post-procedure
Plan to share: Yes — IPD data that underlie the results reported in this article, after deidentification (text, tables, figures)
Supporting information: Study protocol
Time frame: Beginning 1 month and ending 3 years following article publication.
Access criteria: Researches who provide a methodologically sound proposal to achieve aims in the approved proposal. proposals should be directed to yvorobeychik@pennstatehealth.psu.edu.
No publications or documents are linked to this record.
Start is estimated for Aug 2027; primary completion for Dec 2028, 16 months later.
Of 53 non-industry interventional studies with no phase under Spondylosis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 42. This study's planned 16 months is above that.
Counting every sponsor, half of 58 studies reached it within 24 months; a quarter within 6 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Aug 2027, primary completion Dec 2026 → Dec 2028 and completion Dec 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Milton S. Hershey Medical Center →